Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies? [PDF]
Marine Drugs, 2023 Antibodies represent a relatively mature detection means and serve as therapeutic drug carriers in the clinical diagnosis and treatment of cancer—among which monoclonal antibodies (mAbs) currently occupy a dominant position.
Xiaofeng Jiang +5 more
doaj +2 more sources
Journal of Immunology Research, 2020 Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised therapeutic response. The impact of ADA on the bioavailability and clinical efficacy of blockbuster anti-hTNF-α monoclonal ...
Obinna C. Ubah +2 more
doaj +2 more sources
Synthetic libraries of shark vNAR domains with different cysteine numbers within the CDR3.
PLoS ONE, 2019 The variable domain of New Antigen Receptors (vNAR) from sharks, present special characteristics in comparison to the conventional antibody molecules such as: small size (12-15 kDa), thermal and chemical stability and great tissue penetration, that makes
Olivia Cabanillas-Bernal +5 more
doaj +3 more sources
Generation of shark single-domain antibodies as an aid for Cryo-EM structure determination of membrane proteins: Use hyaluronan synthase as an example [PDF]
Journal of Structural Biology: XIn cartilaginous fish, the immunoglobulin new antigen receptor (IgNAR) is naturally devoid of light chains. The variable regions of IgNAR (VNARs) are solely responsible for antigen recognition, similar to VHHs (variable domain of the heavy chain of heavy-
Penghui Deng +6 more
doaj +2 more sources
The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library [PDF]
Communications BiologyCancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies.
Gihan S. Gunaratne +15 more
doaj +2 more sources
vNARs as Neutralizing Intracellular Therapeutic Agents: Glioblastoma as a Target [PDF]
AntibodiesGlioblastoma is the most prevalent and fatal form of primary brain tumors. New targeted therapeutic strategies for this type of tumor are imperative given the dire prognosis for glioblastoma patients and the poor results of current multimodal therapy.
Alejandro Manzanares-Guzmán +2 more
openaire +4 more sources
The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors [PDF]
Nature CommunicationsThe pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) is synthesized as transmembrane TNF-α (tmTNF-α) where proteolytic processing releases soluble TNF-α (sTNF-α).
Obinna C. Ubah +13 more
doaj +2 more sources
Frontiers in Immunology, 2017 Induced costimulatory ligand (ICOSL) plays an important role in the activation of T cells through its interaction with the inducible costimulator, ICOS. Suppression of full T cell activation can be achieved by blocking this interaction and has been shown
Marina Kovaleva +2 more
exaly +3 more sources
Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2 [PDF]
Frontiers in Immunology, 2023 The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generated a joint global effort to develop vaccines and other treatments that could mitigate the negative effects and the rapid spread of the virus.
Olivia Cabanillas-Bernal +4 more
doaj +2 more sources
Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections [PDF]
Frontiers in ImmunologyAntibodies represent indispensable tools in the armamentarium against infectious diseases, with widespread application in prophylactic, therapeutic, and diagnostic settings.
Ammar A. Basabrain +3 more
doaj +2 more sources